DXR
DAXOR CORP
NASDAQ · Healthcare · Medical - Instruments & Supplies · US
$9.84
−2.09%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- -98.5%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -87.9%
- EBITDA
- +14.6%
- EBIT
- +20.5%
- Net income
- +21.0%
- EPS
- +45.3%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026